MIR608

Summary

MIR608 (microRNA 608, HGNC:32864) is a microRNA gene on chromosome 10q24.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693193 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32864
Approved symbol	MIR608
Name	microRNA 608
Location	10q24.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-608
Ensembl gene	ENSG00000207551
Ensembl biotype	miRNA
Entrez	693193
RNAcentral	URS000075A578 — miRNA, 100 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384820

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384820 — 1 exons

Exon	Start	End
ENSE00001499827	100974985	100975084

Expression profiles

Bgee: expression breadth broad, 87 present calls, max score 76.31.

Top tissues by expression

87 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
liver	UBERON:0002107	76.31	gold quality
right lobe of liver	UBERON:0001114	75.49	gold quality
rectum	UBERON:0001052	75.41	gold quality
blood	UBERON:0000178	75.23	gold quality
transverse colon	UBERON:0001157	74.35	gold quality
muscle of leg	UBERON:0001383	73.77	gold quality
colon	UBERON:0001155	73.68	gold quality
gastrocnemius	UBERON:0001388	73.53	gold quality
urinary bladder	UBERON:0001255	73.13	gold quality
intestine	UBERON:0000160	72.93	gold quality
pancreas	UBERON:0001264	72.93	gold quality
heart left ventricle	UBERON:0002084	72.85	gold quality
body of pancreas	UBERON:0001150	72.52	gold quality
right adrenal gland cortex	UBERON:0035827	71.76	gold quality
kidney	UBERON:0002113	71.48	gold quality
stomach	UBERON:0000945	71.21	gold quality
muscle layer of sigmoid colon	UBERON:0035805	71.06	gold quality
calcaneal tendon	UBERON:0003701	71.03	gold quality
adrenal gland	UBERON:0002369	70.63	gold quality
adrenal tissue	UBERON:0018303	70.40	gold quality
body of stomach	UBERON:0001161	70.00	gold quality
left adrenal gland	UBERON:0001234	70.00	gold quality
corpus callosum	UBERON:0002336	69.98	gold quality
small intestine	UBERON:0002108	69.97	gold quality
Brodmann (1909) area 9	UBERON:0013540	69.82	gold quality
small intestine Peyer’s patch	UBERON:0003454	69.62	gold quality
right adrenal gland	UBERON:0001233	69.14	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	69.02	gold quality
substantia nigra	UBERON:0002038	69.00	gold quality
descending thoracic aorta	UBERON:0002345	68.92	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.66

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• rs4919510:C>G in mature miR-608 may influence HER2-positive breast cancer risk and tumor proliferation. (PMID:22586447)
• There was no significant association between rs4919510 and colorectal cancer risk; however, the GG genotype was associated with an increased risk of death in Caucasians and with a reduced risk of death in African Americans. (PMID:22606253)
• Polymorphism in the MIR608 gene was associated with chronic Achilles tendinopathy. (PMID:23347277)
• miR-608 rs4919510C > G exhibited a consistent association with nasopharyngeal carcinoma locoregional recurrence (PMID:23796562)
• Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells (PMID:24339958)
• miR-608 and miR-34a regulate chordoma malignancy by regulating EGFR, MET and Bcl-xL (PMID:24621885)
• miR-608 targets acetylcholinesterase (AChE) and demonstrate weakened miR-608 interaction with the rs17228616 AChE allele having a single-nucleotide polymorphism (SNP) in the 3’-untranslated region (3’UTR). (PMID:24722204)
• miR149 rs2292832 (C>T) is associated with the risk and clinical characteristics of hepatocellular carcinoma while miR608 rs4919510 (G>C) is not. (PMID:25190221)
• Single nucleotide polymorphism in mir608 is associated with colorectal cancer. (PMID:25368035)
• MicroRNA-602 and microRNA-608 regulate sonic hedgehog expression via target sites in the coding region in human chondrocytes. (PMID:25385442)
• potential to modulate HLA-G expression is proposed, in which some microRNAs, such as miR-139-3p, would bind to non-polymorphic sequences of the HLA-G 3’UTR in a stable and specific manner, while others, such as miR-608, binds to polymorphic sequences (PMID:25700346)
• Rs4919510C>G of miR-608 may be a susceptible biomarker of NPC in China. (PMID:25861865)
• Data show that micrRNA miR-608 exerts its anti-cancer function by directly targeting macrophage migration inhibitory factor (MIF) in hepatocellular carcinoma (HCC). (PMID:26474589)
• The results implicate miR-342-5p and miR-608 in colon cancer development and unveil the underlying mechanism of this phenomenon, which involves NAA10. (PMID:26646451)
• MiR-608 polymorphism is associated with hepatocellular carcinoma. (PMID:26815502)
• rs4919510 not significantly associated with breast cancer risk (PMID:26886638)
• miR-608 overexpression inhibits the malignant behavior of glioma stem cells by downregulating MIF. (PMID:26935642)
• The present study aimed to evaluate the impact of miR-608 rs4919510 C>G variant on breast cancer (BC) risk. The findings showed that GC genotype significantly decreased the risk of BC (odds ratio (OR) = 0.49, 95% confidence interval (CI) 0.28-0.88, p = 0.018) compared to CC genotype. (PMID:27031722)
• Results indicatedthat miR-608 rs4919510 polymorphism may contribute to the decreased cancer susceptibility and could be a promising target to forecast cancer risk for clinical practice [Meta-Analysis]. (PMID:27223084)
• miR-608 CC genotype is associated with worse outcome when compared to the CG/GG genotypes in rectal cancer patients treated with neoadjuvant systemic chemotherapy followed by CRT, surgery and adjuvant chemotherapy. (PMID:27381831)
• MIR608 polymorphisms are associated with the risk of head and neck squamous cell carcinoma. (PMID:27515039)
• genotype CC and allele C of miR-608 rs4919510 could decrease predisposition to 0-II stage CRC, mutants of pre-miR-124-1 rs531564 and pre-miR-26a-1 rs7372209 increased recurrent risk in surgically resected CRC individuals receiving adjuvant chemo-radiotherapy and II stage patients, respectively. (PMID:27713147)
• We obtained, however, moderate to weak evidence for replication in one case; specifically, rs4919510 in MIR608 had a p-value of 5.1x10-3 for association with Achilles tendon injury, corresponding to a 7% chance of false replication (PMID:28358823)
• These findings provide evidence that the miR-608 rs4919510 polymorphism may modify cancer susceptibility in a type-specific manner. Furthermore, SEMA4G may function as an oncogene or tumour suppressor to regulate tumour development in a type-specific manner. Further studies with experimental evaluations are warranted. (PMID:28653886)
• In the present meta-analysis, no relationships between miR-608 rs4919510 polymorphism (C>G) and the risk of breast cancer were found. (PMID:28829821)
• During gemcitabine resistance induction in pancreatic cancer cells, miR-608 which is targeting RRM1 and CDA is downregulated which leads to upregulation of these genes. (PMID:28887583)
• Authors present the first evidence that miR-608 behaves as a tumour suppressor in A549 and SK-LU-1 cells through the regulation of AKT2. (PMID:29075783)
• The CC genotype of rs4919510 of miR608 contributes to the metastatic features of the colorectal cancer. (PMID:29412127)
• miR-608 inhibits hepatocellular carcinoma cell proliferation possibly via targeting BET family protein BRD4. (PMID:29777702)
• The rs4919510 polymorphism in miR-608 is associated with cancer risk and prognosis (meta-analysis). (PMID:29909406)
• GG genotype of mir608:rs4919510 had a 4.56-fold increased risk of high expression of IL-6 compared with patients with the CC genotype and is associated with Esophageal Squamous Cell Carcinoma. (PMID:29948421)
• MIR608 suppressed lung adenocarcinoma invasion and migration by targeting MIF protein. (PMID:30070326)
• Low miR608 expression is associated with gastric cancer. (PMID:30453063)
• Studied microRNA 4513 and microRNA 608 single nucleotide polymorphisms (SNPs) as biomarkers in prognosis and survival in epidermal growth factor receptor targeted tyrosine kinase inhibitor treated lung adenocarcinoma patients and in an in vivo model. (PMID:30552364)
• the miRNA-608 rs4919510 G>C polymorphism may have a coronary artery lesion-related relationship with Kawasaki disease susceptibility (PMID:31043452)
• Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3’-UTRs of RAC2/BCL2L1 and the coding region of PAK4. (PMID:31389670)
• the increased cisplatin sensitivity induced by miR608 overexpression was reversed by transfection of TEAD2 in nonsmall cell lung cancer (NSCLC) cells. The present data suggested that miR608 may represent a novel candidate biomarker for the evaluation of cisplatin sensitivity in patients with NSCLC. (PMID:31485614)
• MiR-608 Exerts Anti-inflammatory Effects by Targeting ELANE in Monocytes. (PMID:31749032)
• he upregulation of miR-608 reduced the expression of HOXC4 in the uveal melanoma cells, which was rescued by overexpression of MALAT1. Hence, MALAT1 could upregulate the HOXC4 by binding to miR-608. (PMID:31913701)
• miR-608 rs4919510 Polymorphism May Affect Susceptibility to Colorectal Cancer by Upregulating MRPL43 Expression. (PMID:33147064)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.